Schering-Plough Corporation (NYSE: SGP), a leader in hepatitis research, today reported top- line results of the IDEAL study, the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C: PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy vs. Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP) combination ...
From: www.centredaily.com
Monday, January 14, 2008
Schering-Plough Reports Top-Line Results of the IDEAL Study
Subscribe to:
Post Comments (Atom)
![Digitalpoint Geo Tracking [Enabled]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_sNYQLabaDYq_Xtup8Cdmj2DL9X4_0rszBKOkTdvJaVkfY4Nnzsi0jS3wbFYhREmSwxuzCf988Nfx-JBbUUNg7sDkIDgg=s0-d)
![PingOmatic AutoDiscovery [Enabled]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vStLq0TSzzb5dNPgU3XrY_dvYBl4gk9AAt3yXFsKpRz7gmy8rHQevd3tA9P6ryblWW0TXlK8_YTfkt0DdqFzYgFMVoG-QOgKY-S4QETsSPqvYSYX9-XUAX3w4_de14=s0-d)
![Made with Palestinian Efforts [True]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tTG4dM6hgcyLGERuXBAhWMJP7JUBwPxlBvhbgjjPWpn6r8wHkt6IkD2YBb0UXCDfqjemUvzLrMIqfTEUt4ya2-yGDwzFgOMNM2duGUm1r0CtlGeFVzXT29Mg=s0-d)
No comments:
Post a Comment